Update: AbbVie Shares Rise After FDA Gives 2 Breakthrough Designations for Cancer Drug
MT newswire2026/10/07 18:2002:20 PM EDT, 10/07/2026 (MT Newswires) -- (Updates with stock movement in the headline and first paragraph.) AbbVie (ABBV) shares rose 2.3% in Wednesday trading after the company said the US Food and Drug Administration granted two Breakthrough Therapy Designations for its experimental cancer drug telisotuzumab adizutecan. One designation covers the drug in combination with bevacizumab for adults with hard-to-treat metastatic colorectal cancer who have already received multiple standard therapies, AbbVie said. The second is for use as a standalone treatment in certain adults with advanced non-small cell lung cancer whose tumors express the c-Met protein and who have previously been treated with platinum chemotherapy and an anti-PD-(L)1 therapy. AbbVie said the designations were based mainly on results from its first-in-human study, M21-404. Price: 272.82, Change: +6.13, Percent Change: +2.30
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SNT Holdings, Related Party Raise Combined Stake in SNTEnergy to 55.75% From 52.75%
Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high
Japan's spot electricity prices surged to multi-year highs over the weekend.
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.
Canaccord Genuity: Lowers Oklo's target price to $66
Crypto prices
More
